Help save lives this holiday season
Survival statistics for vaginal cancer
Survival statistics for vaginal cancer are very general estimates and must be interpreted very carefully. Because these statistics are based on the experience of groups of people, they cannot be used to predict a particular person’s chances of survival.
There are many different ways to measure and report cancer survival statistics. Your doctor can explain the statistics for vaginal cancer and what they mean to you.
Relative survival looks at how likely people with cancer are to survive after their diagnosis compared to people in the general population who do not have cancer, but who share similar characteristics (such as age and sex).
In Canada, a separate 5-year relative survival statistic is not reported for vaginal cancer, but is included in the general category, other and unspecified female genital organ cancers. This broad category includes similar cancers that are grouped and reported together. This statistic does not necessarily reflect the actual survival for the individual cancers within the group. The 5-year relative survival for all other and unspecified female genital organ cancers is 64%. This means that, on average, women diagnosed with other and unspecified female genital organ cancers are 64% as likely to live 5 years after their diagnosis as people in the general population.
Survival by stage
Survival varies with each stage, grade and particular type of vaginal cancer. Generally, the earlier vaginal cancer is diagnosed and treated, the better the outcome.
|Stage||5-year relative survival|
III and IV
Questions about survival
People with cancer should talk to their doctor about their prognosis. Prognosis depends on many factors, including:
- a person’s medical history
- type of cancer
- characteristics of the cancer
- treatments chosen
- response to treatment
Only a doctor familiar with these factors can put all of this information together with survival statistics to arrive at a prognosis.
Clinical trial discovery improves quality of life
A clinical trial led by the Society’s NCIC Clinical Trials group found that men with prostate cancer who are treated with intermittent courses of hormone therapy live as long as those receiving continuous therapy.